ArticleAnnals of clinical and translational neurology2024
Fatigue predicts quality of life after leucine-rich glioma-inactivated 1-antibody encephalitis.
Article in Annals of clinical and translational neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Systematic Review and Meta-Analysis of the Clinical Features Associated With Seronegative Autoimmune Encephalitis.Neurology(R) neuroimmunology & neuroinflammation · 2026Pooled it
- Investigating health related quality of life and clinical measures in autoimmune encephalitis: a systematic review.Orphanet journal of rare diseases · 2025Pooled it
- The cascade to pathogenicity in autoantibody-mediated CNS diseases.Brain : a journal of neurology · 2026Review
- Long-Term Outcomes in Autoimmune Encephalitis: A Nationwide, Clinical Study in Denmark.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Plasma proteome in LGI-1 autoimmune encephalitis.Journal of neuroinflammation · 2026Article
- The Treatment of Antibody-Mediated Encephalitis: Current, Future Therapies, Unmet Need and Patient Management.Advances in therapy · 2026Review
- A qualitative exploration of patient experiences living with autoimmune encephalitis.Scientific reports · 2026Article
- Development of anti-LGI1 autoimmune encephalitis outcome rating score using the Rasch analysis.Journal of neurology · 2025Article
- The gut microbiome associated with LGI1-antibody encephalitis.Epilepsia · 2025Article
- Cytokine, Chemokine, and Neurofilament Light Chain Signatures in LGI1 Autoimmune Encephalitis.Annals of clinical and translational neurology · 2025Article
- Cognitive and Patient-Reported Outcome Measures in LGI-1-IgG Autoimmune Encephalitis.Annals of clinical and translational neurology · 2025Article
- Capturing what matters: Patient-reported LGI1-ANTibody encephalitis outcome RatiNg scale (LANTERN).Annals of clinical and translational neurology · 2025Article
- Cognitive Deficits in Anti-LGI1 Encephalitis Are Linked to Immunotherapy-Resistant White Matter Network Changes.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- LGI1-antibody encephalitis: how to approach this highly treatable dementia mimic in memory and mental health services.The British journal of psychiatry : the journal of mental science · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 10 institutions in 4 countries.
Funding
Abstract
Patient-reported quality-of-life (QoL) and carer impacts are not reported after leucine-rich glioma-inactivated 1-antibody encephalitis (LGI1-Ab-E). From 60 patients, 85% (51 out of 60) showed one abnormal score across QoL assessments and 11 multimodal validated questionnaires. Compared to the premorbid state, QoL significantly deteriorated (p < 0.001) and, at a median of 41 months, fatigue was its most important predictor (p = 0.025). In total, 51% (26 out of 51) of carers reported significant burden. An abbreviated five-item battery explained most variance in QoL. Wide-ranging impacts post-LGI1-Ab-E include decreased QoL and high caregiver strain. We identify a rapid method to capture QoL in routine clinic or clinical trial settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.